Engineers Gate Manager LP Regenxbio Inc. Transaction History

Engineers Gate Manager LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$11.51 - $21.53 $229,820 - $429,889	19,967 New	19,967 $233,000
Q4 2023 Feb 14, 2024	BUY	$12.89 - $20.82 $328,785 - $531,055	25,507 New	25,507 $457,000
Q1 2022 May 16, 2022	SELL	$24.62 - $34.31 $487,402 - $679,235	-19,797 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$30.19 - $40.28 $597,671 - $797,423	19,797 New	19,797 $647,000
Q2 2021 Aug 16, 2021	SELL	$32.46 - $40.48 $632,190 - $788,388	-19,476 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$33.61 - $49.95 $443,181 - $658,640	13,186 Added 209.63%	19,476 $664,000
Q4 2020 Feb 16, 2021	SELL	$26.52 - $49.35 $162,726 - $302,811	-6,136 Reduced 49.38%	6,290 $285,000
Q3 2020 Nov 16, 2020	BUY	$27.01 - $40.26 $335,626 - $500,270	12,426 New	12,426 $342,000
Q1 2020 May 15, 2020	SELL	$21.5 - $54.2 $164,475 - $414,630	-7,650 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$34.54 - $44.87 $264,231 - $343,255	7,650 New	7,650 $313,000
Q3 2019 Nov 14, 2019	SELL	$31.84 - $50.88 $635,812 - $1.02 Million	-19,969 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$42.0 - $59.29 $838,698 - $1.18 Million	19,969 New	19,969 $1.03 Million

197

43.2M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $439M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.